ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 110 filers reported holding ALDEYRA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.77 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,253,192 | -20.0% | 3,031,915 | +0.5% | 21.02% | -31.5% |
| Q2 2023 | $25,301,454 | +23.3% | 3,015,668 | +45.9% | 30.67% | -3.0% |
| Q1 2023 | $20,526,898 | +51.4% | 2,067,160 | +6.1% | 31.64% | +3.4% |
| Q4 2022 | $13,558,706 | +35.2% | 1,948,090 | +3.8% | 30.60% | +422.4% |
| Q3 2022 | $10,025,000 | +67.2% | 1,877,305 | +24.9% | 5.86% | +71.2% |
| Q2 2022 | $5,995,000 | +77.6% | 1,502,460 | +97.8% | 3.42% | +61.5% |
| Q1 2022 | $3,376,000 | +11.1% | 759,405 | 0.0% | 2.12% | +27.0% |
| Q4 2021 | $3,038,000 | -39.2% | 759,405 | +33.4% | 1.67% | -33.1% |
| Q3 2021 | $4,999,000 | -22.5% | 569,405 | 0.0% | 2.49% | -26.0% |
| Q2 2021 | $6,451,000 | -4.6% | 569,405 | 0.0% | 3.37% | -23.6% |
| Q1 2021 | $6,765,000 | +73.2% | 569,405 | 0.0% | 4.41% | +65.5% |
| Q4 2020 | $3,906,000 | -7.4% | 569,405 | 0.0% | 2.66% | -23.0% |
| Q3 2020 | $4,219,000 | +77.7% | 569,405 | 0.0% | 3.46% | +152.2% |
| Q2 2020 | $2,374,000 | +68.8% | 569,405 | 0.0% | 1.37% | +3.8% |
| Q1 2020 | $1,406,000 | -57.5% | 569,405 | 0.0% | 1.32% | -45.9% |
| Q4 2019 | $3,308,000 | +18.1% | 569,405 | +7.1% | 2.44% | -4.7% |
| Q3 2019 | $2,801,000 | -11.8% | 531,568 | +0.4% | 2.56% | -1.4% |
| Q2 2019 | $3,176,000 | -27.3% | 529,390 | +9.4% | 2.60% | -21.7% |
| Q1 2019 | $4,371,000 | +8.8% | 484,096 | 0.0% | 3.32% | -27.3% |
| Q4 2018 | $4,018,000 | -36.4% | 484,096 | 0.0% | 4.57% | -14.4% |
| Q3 2018 | $6,317,000 | +540.0% | 484,096 | +290.1% | 5.34% | +536.5% |
| Q2 2018 | $987,000 | +6.0% | 124,096 | 0.0% | 0.84% | -12.2% |
| Q1 2018 | $931,000 | +10.3% | 124,096 | 0.0% | 0.96% | +28.5% |
| Q4 2017 | $844,000 | -5.5% | 124,096 | 0.0% | 0.74% | -2.6% |
| Q3 2017 | $893,000 | +53.2% | 124,096 | 0.0% | 0.76% | -1.2% |
| Q2 2017 | $583,000 | -6.0% | 124,096 | 0.0% | 0.77% | -17.3% |
| Q1 2017 | $620,000 | -14.7% | 124,096 | -8.6% | 0.94% | -26.7% |
| Q4 2016 | $727,000 | -30.0% | 135,800 | 0.0% | 1.28% | -29.9% |
| Q3 2016 | $1,038,000 | +34.3% | 135,800 | 0.0% | 1.82% | +625.1% |
| Q2 2016 | $773,000 | +35.9% | 135,800 | 0.0% | 0.25% | +8.7% |
| Q1 2016 | $569,000 | -38.2% | 135,800 | 0.0% | 0.23% | -32.3% |
| Q4 2015 | $921,000 | +16.3% | 135,800 | 0.0% | 0.34% | +1.5% |
| Q3 2015 | $792,000 | -24.9% | 135,800 | 0.0% | 0.34% | -1.2% |
| Q2 2015 | $1,054,000 | -23.7% | 135,800 | 0.0% | 0.34% | -15.4% |
| Q1 2015 | $1,382,000 | – | 135,800 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
| Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
| Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
| Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
| Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
| Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
| Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
| Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
| APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |